Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

7
Skyworks Solutions, Inc. (SWKS) CEO Liam Griffin on Q3 2018 Results - Earnings Call Transcript

1h seekingalpha
Good afternoon, and welcome to Skyworks Solutions' Third Quarter Fiscal Year 2018 Earnings Call. This call is being recorded. At this time, I will turn the call over to Mitch Haws, Vice President of Investor Relations for Skyworks. Mr. Haws please go ahead.
CHLKF MS.PRE MS.PRF SW MS.PRG MS.PRA 0941 SWIR SWKS 0762 MS.PRI CHL MS.PRK CHUFF MS CHU

5
RPT-'Medical check-ups': Japan firms tap banks for advice as activists circle

1h reuters
TOKYO, July 20 (Reuters) - Japanese companies are increasingly turning to investment banks and public relations firms for advice on dealing with potential approaches by activist investors who are targeting low valuations and cross-shareholdings in the nation.
PCRFY 6816 MS.PRI MS.PRK MS.PRE MS.PRF AELEF MS.PRG SNE MS MS.PRA SNEJF

0
Nordea Bank's (NRBAY) CEO Casper von Koskull on Q2 2018 Results - Earnings Call Transcript

2h seekingalpha
Nordea Bank AB ADR (OTCPK:NRBAY) Q2 2018 Earnings Conference Call July 19, 2018 3:00 AM ET
DB MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG NRBAY MS MS.PRA

5
Microsoft Corp. (MSFT) CEO Satya Nadella on Q4 2018 Results - Earnings Call Transcript

2h seekingalpha
Greetings and welcome to the Microsoft Fiscal Year 2018 Fourth Quarter Earnings Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
WFC WFCNP WFC.WS DB MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT WFC.PRR WFC.PRQ MS.PRI WFC.PRP WFC.PRO WFC.PRN MS.PRK MSFT WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV

0
Saudis Pump More Oil to Please Trump, Then Doubt If It's Needed - Bloomberg

2h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MS.PRI SCGLF MS.PRK MS.PRE MS.PRF SCGLY MS.PRG GLE MS MS.PRA

13
Fintech is ‘resilient’ in a way tech isn’t, says Morgan Stanley - MarketWatch

4h marketwatch
Analysts upgrade the payments sector to attractive, arguing that ‘these are some of the best businesses there are’
LC GSKY MS.PRE MS.PRF MA MS.PRG PYPL MS.PRA V MS.PRI ONDK MS.PRK MS FLT

5
'Medical check-ups': Japan firms tap banks for advice as activists circle

5h reuters
TOKYO (Reuters) - Japanese companies are increasingly turning to investment banks and public relations firms for advice on dealing with potential approaches by activist investors who are targeting low valuations and cross-shareholdings in the nation.
PCRFY 6816 MS.PRI MS.PRK MS.PRE MS.PRF AELEF MS.PRG SNE MS MS.PRA SNEJF

1
United Rentals, Inc. (URI) CEO Michael Kneeland on Q2 2018 Results - Earnings Call Transcript

6h seekingalpha
Good afternoon, and welcome to the United Rentals Investor Conference Call. Please be advised that this call is being recorded.
CMQMY MS.PRI MS.PRK URI MS.PRE MS.PRF MS.PRG NEFF MS MS.PRA CMI

1
Endava Proposes Terms For $101 Million U.S. IPO

6h seekingalpha
DAVA is growing quickly and has shown enviable financial results; competition will be stiff in its new region of focus, North America.
11IE MS.PRI 42KM MS.PRK 42MA MS.PRE MS.PRF MSP MS.PRG MS MS.PRA

0
Union Pacific Corporation (UNP) CEO Lance Fritz on Q2 2018 Results - Earnings Call Transcript

6h seekingalpha
Union Pacific Corporation (NYSE:UNP) Q2 2018 Results Earnings Conference Call July 19, 2018 8:45 AM ET
DB MS.PRI UNP MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

1
Microsoft Sales Top Estimates With More Clients Signing Up for Cloud - Bloomberg

7h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
IT MS.PRI MS.PRK MS.PRE MS.PRF MSFT MS.PRG MS MS.PRA

0
Dow remains lower by 100 points after Trump criticizes Federal Reserve

7h cnbc
Stocks fell on Thursday amid criticism of the Federal Reserve by President Donald Trump. A decline in bank shares also pushed the broader market down.
PRU MS.PRI MS.PRK PRH PFK MS.PRE MS.PRF MS.PRG MS MS.PRA PJH

4
Are Large-Cap India ETFs Good Bets for 2H?

7h zacks
After a solid rally last year, India ETFs slowed down this year. The pain was rather brutal in the small-cap space, thanks to overvaluation concerns. Columbia India Small Cap ETF (SCIN - Free Report) is thus off 28.5% in the year-to-date frame (as of Jul 17, 2018) and the large-cap fund iShares India 50 ETF (INDY - Free Report) has lost about 1.9%.
WFC WFCNP WFC.WS SCIN INDY MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT WFC.PRR WFC.PRQ MS.PRI WFC.PRP WFC.PRO WFC.PRN MS.PRK WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV

1
Taiwan Semiconductor Manufacturing's (TSM) CEO C. C. Wei on Q2 2018 Results - Earnings Call Transcript

7h seekingalpha
Taiwan Semiconductor Manufacturing Co Ltd (NYSE:TSM) Q2 2018 Earnings Conference Call July 19, 2018 2:00 AM ET
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA TSM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 61761J406